Advanced non-small-cell lung cancer: new data, therapy choices, and challenging decisions.
Sandler
Alan B
AB
Division of Hematology/Oncology, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001688:Biological Products / Q000627:therapeutic use; D035843:Biomedical Research / Q000639:trends; D002289:Carcinoma, Non-Small-Cell Lung / Q000503:physiopathology / Q000628:therapy*; D016503:Drug Delivery Systems / Q000639:trends; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000503:physiopathology / Q000628:therapy*; D008495:Medical Oncology / Q000639:trends*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001688:Biological Products; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; C512478:EGFR protein, human; D066246:ErbB Receptors; D000077156:Gefitinib